Despite the disease’s prevalence, endometriosis remains misunderstood, and research into drugs that might treat it draws scant funding — problems that have deep roots.
The firm’s co-founders claim to be pursuing a “contrarian” approach, building a team versed in both computing and life sciences and concentrating resources on a smaller number of bets.